Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4162 | Stools Wiki | 0.26 |
| drug4454 | Traditional antirheumatic drugs Wiki | 0.26 |
| drug729 | C3+ Holter Monitor Wiki | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug734 | CAP-1002 Wiki | 0.26 |
| drug4866 | blood tests Wiki | 0.26 |
| drug3353 | Pravastatin Wiki | 0.26 |
| drug5136 | placebo rinse Wiki | 0.26 |
| drug2001 | Hydroxychloroquine/Chloroquine Wiki | 0.26 |
| drug751 | CETA Short Session (CSS) Wiki | 0.26 |
| drug3436 | Psychoeducation and Safety Wiki | 0.26 |
| drug2478 | MSB11456 Wiki | 0.26 |
| drug1432 | EU-approved RoActemra Wiki | 0.26 |
| drug764 | CK0802 Wiki | 0.26 |
| drug1495 | Enbrel Wiki | 0.26 |
| drug727 | C21 Wiki | 0.26 |
| drug765 | CLBS119 Wiki | 0.26 |
| drug741 | CCP Wiki | 0.26 |
| drug1668 | Filgotinib Wiki | 0.26 |
| drug723 | Buspirone 10 Mg Oral Tablet Wiki | 0.26 |
| drug743 | CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc Wiki | 0.26 |
| drug285 | Alternating face-to-face medical visits and video medical consultations Wiki | 0.26 |
| drug744 | CD24Fc Wiki | 0.26 |
| drug754 | CGB-S-100 Wiki | 0.26 |
| drug4508 | Triazolam 0.25 MG Oral Tablet Wiki | 0.26 |
| drug4034 | Sofusa DoseConnect Wiki | 0.26 |
| drug758 | CHLORPROMAZINE (CPZ) Wiki | 0.26 |
| drug3932 | Serological analyses to be lead on a pre-existing biobank Wiki | 0.26 |
| drug1633 | Face-to-face medical visits Wiki | 0.26 |
| drug760 | CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) Wiki | 0.26 |
| drug716 | Bucillamine Wiki | 0.18 |
| drug2763 | Nasopharyngeal swabs Wiki | 0.18 |
| drug697 | Brequinar Wiki | 0.18 |
| drug1737 | GLPG3970 Wiki | 0.18 |
| drug413 | Atorvastatin Wiki | 0.15 |
| drug3724 | Rosuvastatin Wiki | 0.13 |
| drug5171 | questionnaire assesment Wiki | 0.12 |
| drug4104 | Standard of Care (SOC) Wiki | 0.12 |
| drug3215 | Placebo Administration Wiki | 0.12 |
| drug3195 | Placebo Wiki | 0.07 |
| drug3273 | Placebo oral tablet Wiki | 0.04 |
| drug1950 | Hydroxychloroquine Wiki | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001168 | Arthritis NIH | 0.87 |
| D025241 | Spondylarthritis NIH | 0.39 |
| D013166 | Spondylitis NIH | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013167 | Spondylitis, Ankylosing NIH | 0.26 |
| D015535 | Arthritis, Psoriatic NIH | 0.23 |
| D001167 | Arteritis NIH | 0.18 |
| D003095 | Collagen Diseases NIH | 0.17 |
| D012216 | Rheumatic Diseases NIH | 0.16 |
| D011111 | Polymyalgia Rheumatica NIH | 0.15 |
| D013700 | Giant Cell Arteritis NIH | 0.15 |
| D012859 | Sjogren's Syndrome NIH | 0.13 |
| D001327 | Autoimmune Diseases NIH | 0.12 |
| D008180 | Lupus Erythematosus, Systemic NIH | 0.11 |
| D059350 | Chronic Pain NIH | 0.07 |
| D003141 | Communicable Diseases NIH | 0.04 |
| D007239 | Infection NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.01 |
| D018352 | Coronavirus Infections NIH | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001370 | Rheumatoid arthritis HPO | 1.00 |
| HP:0001369 | Arthritis HPO | 0.87 |
| HP:0012089 | Arteritis HPO | 0.18 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002960 | Autoimmunity HPO | 0.12 |
| HP:0002725 | Systemic lupus erythematosus HPO | 0.11 |
| HP:0012532 | Chronic pain HPO | 0.07 |
Navigate: Correlations HPO
There are 15 clinical trials
This study aims to evaluate the experience of Alberta patients with inflammatory arthritis who participate in the the RAPPORT-ONTRAAC registry during the COVID-19 pandemic, specifically comparing the experience of those taking anti-malarial medications compared to those who do not. This registry includes approximately 2500 northern Alberta patients with inflammatory arthritis who receive highly complex therapies which may be associated with side effects. This program of data collection and research has been evaluating the effectiveness and safety as well as associated health care costs of rheumatoid and psoriatic arthritis patients since 2004. The principle investigators are based at the University of Alberta while the co-investigators are academic rheumatologists at the University of Alberta. The registry has approximately 900 patients taking anti-malarials combined with their complex therapies and ~ 1500 not on anti-malarials in combination with their complex therapies. We aim to perform a case control study evaluating the impact of anti-malarial drugs (eg. hydroxychloroquine and chloroquine) on the development of COVID-19 compared to those patients who are not on anti-malarial drugs over the next 6-12 months. In addition to frequent e-mail surveys screening for the clinical symptoms of COVID-19 and understanding their concomitant arthritis medication use, we will compare the healthcare outcomes of both groups of arthritis patients with and without COVID-19 for the duration of the pandemic. This information will provide critical information beyond an anecdotal level on whether or not anti-malarials truly provide a protective benefit against COVID-19 or reduce the severity of infection. A blood sample from all participants (Covid-19 positive and negative) will be drawn approximately six months into the study for measurement of antibodies to Covid-19 and possible blood types and HLA alleles. Additionally, this study will be linked to another study "Persistence of SARS-Cov2 in immunocompromised patients" which will specifically evaluate COVID-19 serology and nasopharyngeal swab findings in the subset of patients who develop COVID-19.
Description: Number of patients developing signs and symptoms of Covid-19 or other infections
Measure: Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group Time: 12 monthsDescription: Number of patients developing Covid-19 infection
Measure: Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group Time: 12 monthsDescription: Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action
Measure: Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action Time: 12 monthsDescription: Quantitative measurement of Covid-19 serology to understand possible differences in degree of immune response adjusted for anti-malarial and/or biologic exposure
Measure: Quantification of Covid-19 antibodies in anti-malarial vs non-anti-malarial groups of inflammatory arthritis patients Time: 6 monthsClinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration. In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression. During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients. The present study is an "emergency" being realize before the end of the quarantine.
Description: Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.
Measure: self-reported questionnaire for painful Time: maximum 1 week from baseline onThe antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents. Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).
Description: serum level
Measure: immunoglobulin mesurement Time: 1 monthThe current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.
Description: Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD
Measure: Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis Time: 1 DayThe coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.
Description: ELISA tests for COVID-19 antibodies
Measure: COVID-19 seroconversion Time: 1 day, during routine blood collectionDescription: Case report form filled by the health professional
Measure: COVID-19 infection Time: During medical visit or phone consultation, up to 2 hoursDescription: Descriptive analysis for each disease's rate
Measure: Seroconversion rate by disease Time: 1 day, during routine blood collectionDescription: Descriptive analysis for each country's rate
Measure: Penetration across Europe Time: 1 day, during routine blood collectionDescription: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.
Measure: COVID-19 severity Time: During medical visit, up to 1 hourDescription: Descriptive analysis for overall and COVID-19-linked mortality rates
Measure: COVID-19 mortality rate Time: During contact with family members, up to 1 hourDescription: Case report form filled by the health professional
Measure: COVID-19 impact on immunomodulatory treatment Time: During medical visit, up to 1 hourDescription: Case report form filled by the patient
Measure: Patient-reported flares Time: During medical visit, up to 1 hourDescription: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.
Measure: Patient's fears towards COVID-19 Time: During medical visit, up to 1 hourDescription: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.
Measure: Patient's beliefs in their medicines towards COVID-19 Time: During medical visit, up to 1 hourDue to the Covid-19 worldwide outbreak, fragile patients with immune diseases, notably rheumatoid arthritis (RA), have to be even more specifically and carefully followed-up. However, it has been shown that false postive serological results often occured while detecting antibodies directed against SARS-CoV-2 in patients with positive rheumatodoid factor (RF). The investigators propose here to investigated this issue. Therefore, the investigators will test three different immunoassays on this specific population. The investigators aim to establish these assays specificity and the levels of RF for which there is a risk of anti-SARS-CoV-2 false positivity and thus ensure a better follow-up of RA patients. The RF isotype will be analysed to determine whether there is a correlation and the impact of the presence of anti-CCP (citrullinated cyclic antipeptide antibodies) will be studied and assessed.
Description: Evaluate the false positive results rate when using each one of the three SARS-CoV-2 serology tests in patients with rheumatoid factor plasma levels, so as to define the specificity of these tests in this RA population. all serum samples will be tested by the 3 different immunoassays. The RF plasma levels have already been measured (routine exam) and are written in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the question.
Measure: Evaluate the false positive results rate Time: 4 monthsDescription: Characterize the RF isotype (IgG, IgM or IgA) associated with the false positivity of the test.all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions
Measure: Characterize the RF isotype (IgG, IgM or IgA) associated Time: 4 monthsDescription: Determine the influence of RA on the false positivity rate in subjects with negative RF titer. All serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions
Measure: Determine the influence of RA on the false positivity rate in subjects Time: 4 monthsDescription: Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test : all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions.
Measure: Assess the influence of the presence of anti-CCP on the false positivity of the SARS-CoV-2 test Time: 4 monthsDescription: Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test : all serum samples will be tested by the 3 different immunoassays. The RF isotype will be established using the routine method and the results of anti-CCP and RF plasma levels are already known and this information is available in the patients files. The results will be analysed, the data proceeded and hopefully we will be able to answer the questions.
Measure: Assess the relation between the RF plasma levels and the false positivity of the SARS-CoV-2 test Time: 4 monthsRheumatoid arthritis (RA) patients have an underlying immune deficiency and typically treated with immunosuppressive drugs, which may increase the risk of COVID-19 infection. Hydroxychloroquine (HCQ) has been found to possess antiviral activity against COVID-19. Thus, the aim of this study to investigate the ability of HCQ to reduce the risk of COVID-19 among RA patients.
Description: Realtion between hydroxychloroquine use and COVID-19 infection
Measure: The risk of COVID-19 infection among RA patients Time: 12 weekDescription: Number of cases and number of hospitalization days
Measure: The incidence of hospitalization for Covid-19 patients. Time: 12 weekThe purpose of the study is to compare the efficacy, safety and immunogenicity of MSB11456 and EU approved RoActemra® in participants with moderately to severely active rheumatoid arthritis. Participants will be randomized at the beginning of the Core Treatment Period (Baseline to Week 24) to receive either MSB11456 or EU approved RoActemra® once a week (QW). At the beginning of the Extended Treatment Period (Week 24 to Week 52), participants who received RoActemra® will be re-randomized to either continue receiving RoActemra® QW or switch to receive MSB11456 QW.
A better understanding of the different phenotypes of COVID 19 in patients with inflammatory rheumatisms, and the persitence of antibodies against SARS CoV-2 in these patients under immunosuppressive drugs are required to propose appropriated recommendations for these patients in order to guide the strategy of vaccination in this immune-depressed population who is not immunized.
Description: Variation of anti-SARS-CoV2 antibodies titers between baseline
Measure: Seroprevalence of COVID-19 in patients with inflammatory rheumatisms Time: 6 monthsDescription: Variation of anti-SARS-CoV2 antibodies titers between baseline
Measure: Seroprevalence of COVID-19 in patients with inflammatory rheumatisms Time: 12 monthsDescription: Coagulation factors in patients with inflammatory rheumatisms compared to health professionals
Measure: Clinical expression of COVID-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion Time: 6 monthsDescription: Coagulation factors in patients with inflammatory rheumatisms compared to health professionals
Measure: Clinical expression of COVID-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion Time: 12 monthsDescription: Coagulation factors in patients with inflammatory rheumatisms compared to health professionals
Measure: Clinical expression of COVID-19 compared to health professionals : phenotypes, thrombo-embolic events and stress repercussion Time: 24 monthsThe COVID-19 outbreak has affected health care of patients with rheumatic diseases; telemedicine might help to assist patients. The primary objective is to determine if a hybrid medical care model, which consists of alternating face-to-face medical visits and video medical consultations, is not inferior, in terms of the Patient Reported Outcomes measures (PROMs), to the face-to-face medical care model, among rheumatoid arthritis (RA) outpatients. We also aim to investigate if adherence to RA-related treatment (considered a surrogate of patient´s education) might be improved when patients are re-integrated to the health care system, irrespective of the health care model. In Mexico, COVID-19 pandemic still uncontrolled. Our Institution provides health care to 1500 RA patients/year and up to August 2020, it is estimated that 500 RA patients might be affected, which is our target audience. Reinstalling institutional health care provision is challenging. This a non-inferiority, cross-over study, with 2 intervention arms. Patients will be randomized to 1. Six months of usual medical care model, followed by 4 months of a control period, and 6 months of hybrid medical care model, or 2. Six months of hybrid medical care model, followed by 4 months of a control period, and 6 months of usual medical care model. The following PROMs will be assessed at specific time points: disease activity/disease severity (RAPID-3), disability (HAQ-DI), quality of life (WHOQOL-BREF), patient satisfaction with the medical care model (questionnaire locally developed), patient´s adherence to medical care (missed scheduled visits) and patient´s adherence to RA-related treatment (the Compliance-Questionnaire).
Description: The disease activity measured by a RAPID-3 instrument
Measure: Rheumatoid arthritis patient´s disease activity Time: During the 16 months of follow up, the evaluations will be in each medical visits (in both medical care models)Description: Quality of life measured by a WHOQOL-BREF instrument
Measure: Rheumatoid arthritis patient´s quality of life Time: During the 16 months of follow up, the evaluations will be in each medical visits (in both medical care models)Description: Disability measured by a HAQ-DI instrument
Measure: Rheumatoid arthritis patient's disability Time: During the 16 months of follow up, the evaluations will be in each medical visits (in both medical care models)Description: Questionnaire locally developed
Measure: Satisfaction with medical care Time: During the 16 months of follow up, the evaluations will be in each medical visits (in both medical care models)Description: Number of missed scheduled visits
Measure: Patient´s adherence to medical care Time: During the 16 months of follow up, the evaluations will be in each medical visits (in both medical care models)This is an open-label pilot study in patients with rheumatoid arthritis (RA). All patients will receive SOFUSA Enbrel 25 mg once weekly. The dose will be increased to 50 mg if the dose escalation criteria are met during the dose escalation phase of the study.
Description: Incidence and severity of adverse events and their relationships to SOFUSA administration
Measure: Incidence and severity of adverse events and their relationships to SOFUSA administration Time: Baseline through Week 12Description: Change from Baseline in DAS28(CRP) score at Week 12
Measure: Change in Disease Activity Score 28-joint count C reactive protein (DAS28(CRP)) Time: Baseline to Week 12Description: Change from Baseline in DAS28(CRP) score over time
Measure: Change in DAS28(CRP) score over time Time: Baseline through Week 12Description: Change from Baseline in DAS28(ESR) score over time
Measure: Change in Disease Activity Score 28-joint count erythrocyte sedimentation rate (DAS28(ESR)) over time Time: Baseline through Week 12Description: Change from Baseline in SDAI score over time
Measure: Change in Simplified Disease Activity Index (SDAI) score over time Time: Baseline through Week 12Description: Change from Baseline in CDAI score over time
Measure: Change in Clinical Disease Activity Index (CDAI) score over time Time: Baseline through Week 12Description: Proportion of patients with DAS28(CRP) score < 2.9 over time
Measure: Proportion of patients with low disease activity (LDA) over time as assessed by the DAS28(CRP) Time: Baseline through Week 12Description: Proportion of patients with DAS28(ESR) score ≤ 3.2 over time
Measure: Proportion of patients with LDA over time as assessed by the DAS28(ESR) Time: Baseline through Week 12Description: Proportion of patients with SDAI score ≤ 11.0 over time
Measure: Proportion of patients with LDA over time as assessed by the SDAI Time: Baseline through Week 12Description: Proportion of patients with CDAI score ≤ 10 over time
Measure: Proportion of patients with LDA over time as assessed by the CDAI Time: Baseline through Week 12Description: Proportion of patients achieving ACR20/50/70 response over time
Measure: Proportion of patients achieving ACR20/50/70 response over time Time: Baseline through Week 12Description: Proportion of patients achieving moderate or good EULAR response over time
Measure: Proportion of patients achieving moderate or good EULAR response over time Time: Baseline through Week 12Description: Proportion of patients achieving a MCID of 0.22 in HAQ-DI over time
Measure: Proportion of patients achieving a minimally clinically important difference (MCID) of 0.22 in the Health Assessment Questionnaire-Disability Index (HAQ-DI) over time Time: Baseline through Week 12The primary objective of this study is to evaluate the effect of GLPG3970 compared to placebo on the signs and symptoms of Rheumatoid Arthritis (RA) in participants with moderately to severely active RA and an inadequate response to methotrexate (MTX).
The purpose of this study is to assess whether immunosuppressive therapies used by patients with chronic inflammatory rheumatic diseases have an impact on the viral load and the humoral and cellular responses during viral infection with SarSCoV2, compared to members of their family cluster infected with the same viral strain.
Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA
Measure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs Time: up to Day 30Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNA
Measure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs Time: between Day 30 and Day 90The primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates using phenotypic probes.
The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet been widely reported, and has been evaluated only in symptomatic patient samples. The proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with chronic inflammatory rheumatism with serological testing
Description: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis
Measure: Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis Time: 1 dayDescription: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.
Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments. Time: 1 dayDescription: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease
Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease Time: 1 dayDescription: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics
Measure: Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics Time: 1 dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports